Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ernesto Vigna

Showing results (51-60 of 117) with videos related to

Pageof 12
Sort By:
Expert Opinion on Investigational Drugs|August 3, 2024
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignanciesEnrica Antonia Martino, Antonella Bruzzese, Caterina Labanca, et al.
Expert Review of Hematology|May 15, 2024
The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemiaAntonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, et al.
European Journal of Haematology|April 13, 2025
Rilzabrutinib for the Treatment of Immune ThrombocytopeniaCaterina Labanca, Enrica Antonia Martino, Ernesto Vigna, et al.
European Journal of Haematology|December 26, 2025
Chemotherapy-Sparing Strategies in Follicular Lymphoma: Emerging Targeted and Immune-Based ApproachesEnrica Antonia Martino, Santino Caserta, Mamdouh Skafi, et al.
European Journal of Haematology|February 6, 2026
Targeting Ikaros and Aiolos: Next-Generation Cereblon E3 Ligase Modulators in MMMaria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, et al.
Journal of Geriatric Oncology|March 9, 2025
Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort studyEnrica Antonia Martino, Ernesto Vigna, Paola De Luca, et al.
British Journal of Haematology|June 15, 2026
Minimal residual disease in diffuse large B-cell lymphoma after first-line therapy: Defining the continuum from metabolic remission to molecular clearanceSantino Caserta, Enrica Antonia Martino, Ernesto Vigna, et al.
Chemotherapy|August 16, 2017
Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic TransplantAnnamaria Petrungaro, Massimo Gentile, Carla Mazzone, et al.
European Journal of Haematology|April 2, 2026
Targeting the Menin-KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical TranslationAntonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, et al.
Antibiotics (Basel, Switzerland)|April 27, 2026
Gut Microbiota and Acute Myeloid Leukemia: State of the Art, Clinical Signals, and Translational OpportunitiesMaria Eugenia Alvaro, Santino Caserta, Enrica Antonia Martino, et al.
Pageof 12

Showing results (51-60 of 117) with videos related to

Sort By:
Pageof 12
Expert Opinion on Investigational Drugs|August 3, 2024
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignanciesEnrica Antonia Martino, Antonella Bruzzese, Caterina Labanca, et al.
Expert Review of Hematology|May 15, 2024
The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemiaAntonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, et al.
European Journal of Haematology|April 13, 2025
Rilzabrutinib for the Treatment of Immune ThrombocytopeniaCaterina Labanca, Enrica Antonia Martino, Ernesto Vigna, et al.
European Journal of Haematology|December 26, 2025
Chemotherapy-Sparing Strategies in Follicular Lymphoma: Emerging Targeted and Immune-Based ApproachesEnrica Antonia Martino, Santino Caserta, Mamdouh Skafi, et al.
European Journal of Haematology|February 6, 2026
Targeting Ikaros and Aiolos: Next-Generation Cereblon E3 Ligase Modulators in MMMaria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, et al.
Journal of Geriatric Oncology|March 9, 2025
Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort studyEnrica Antonia Martino, Ernesto Vigna, Paola De Luca, et al.
British Journal of Haematology|June 15, 2026
Minimal residual disease in diffuse large B-cell lymphoma after first-line therapy: Defining the continuum from metabolic remission to molecular clearanceSantino Caserta, Enrica Antonia Martino, Ernesto Vigna, et al.
Chemotherapy|August 16, 2017
Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic TransplantAnnamaria Petrungaro, Massimo Gentile, Carla Mazzone, et al.
European Journal of Haematology|April 2, 2026
Targeting the Menin-KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical TranslationAntonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, et al.
Antibiotics (Basel, Switzerland)|April 27, 2026
Gut Microbiota and Acute Myeloid Leukemia: State of the Art, Clinical Signals, and Translational OpportunitiesMaria Eugenia Alvaro, Santino Caserta, Enrica Antonia Martino, et al.
Pageof 12